Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0002871 (anemia)
 52,094 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 12-day balance study with measurements of urine and stool excretion was undertaken to determine the effects of intravenous (i.v.) Desferal (293 mg/kg/24 h x 2) on iron, aluminum, copper, and zinc in a child with Hemoglobin Hammersmith and Turner's syndrome treated as a thalassemia major patient because of symptoms of anemia and ineffective erythropoiesis. Iron balance was positive, 34 mg/3 days baseline. The Desferal infusion induced iron excretion of 117 mg over 48 h, almost equally in stool and urine. This child receives approximately 20 transfusion/i.v. Desferal treatments yearly. If iron excretion is roughly the same with each treatment, it would equal 2,340 mg or 47% of her annual iron intake from transfusion. The i.v. infusions are an important part of this patient's therapy and may also be useful for other chronic transfusion patients for whom subcutaneous Desferal is inadequate for preventing continued iron accumulation. Some patients have successfully received their i.v. Desferal therapy at home, thereby decreasing hospitalization time and cost. Desferal induced moderate aluminum excretion in urine but had no effect on copper or zinc excretion.
 ...
PMID:Mineral balance (iron, aluminum, copper, zinc) after high-dose intravenous Desferal in a child with hemoglobin Hammersmith and Turner's syndrome. 261 82

In experiments on rats with iron-deficiency diet hemoglobin and erythrocyte number was lowered, whereas the contents of 2.3-DPG and ATP were increased by 40-40%, accordingly. Desferal injections have aggravated the anemia severity. Pathogenetic therapy using myelopid had a favourable effect on the animals with anemia. Similar changes were observed in patients with iron-deficiency anemia.
 ...
PMID:[The regulatory mechanisms of the blood respiratory function in iron-deficiency anemias]. 930 4

The differential ferrioxamine test is a simple method for the measurement of chelation of body iron by desferrioxamine. A single six-hour specimen of urine is obtained after intravenous Desferal, accompanied by (59)Fe-ferrioxamine. Two values are measured: F(d), the excretion of ferrioxamine derived from body iron by chelation, and F(ex), the proportion of ferrioxamine excreted from a known intravenous dose. The data enables F(v), chelation of iron in vivo, to be calculated by simple proportion. Desferrioxamine chelation proceeds for about half an hour after injection. The results in normal subjects, in cases with known high iron stores, and in cases of iron-deficiency anaemia are described. High, normal, and low body iron states have been differentiated. F(v) values in the higher ranges obtained in iron-storage diseases and in haemolytic states are differentiated by the pattern of excretion, high F(d) values and low F(ex) values respectively. IT IS SUGGESTED THAT THERE ARE TWO MAIN SOURCES OF CHELATABLE BODY IRON: as ferritin-haemosiderin and as iron newly released from haem in a more readily chelatable form. The significance of variable chelation susceptibility in iron metabolism is briefly discussed. It is suggested that variable chelatability of different sources of body iron may explain the preferential utilization of iron released from red cells or absorbed from the intestine, rather than storage iron, in the biosynthesis of haem.
 ...
PMID:DIFFERENTIAL FERRIOXAMINE TEST FOR MEASURING CHELATABLE BODY IRON. 1424 11